Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.67 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.67 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.67 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | MAOA | P21397 | 1/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.66 |
| ▸ | SCN1A | P35498 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.66 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.66 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3021901 | 1.00 | CHRM2 (0.67) | CHRM2CHRM4CHRM1CHRM3KCNH2 | |
| SCHEMBL8668263 | 0.87 | CHRM2 (0.63) | CHRM2CHRM4CHRM1CHRM3KCNH2 | |
| Theracys SCHEMBL367470 | 0.82 | KCNH2 (0.80) | KCNH2MAPTMAOASLC6A2SLC6A4 | |
| Theracys SCHEMBL328885 | 0.82 | KCNH2 (0.80) | KCNH2MAPTMAOASLC6A2SLC6A4 | |
| Theracys SCHEMBL116803 | 0.82 | KCNH2 (0.80) | KCNH2MAPTMAOASLC6A2SLC6A4 | |
| Theracys SCHEMBL13196454 | 0.82 | KCNH2 (0.80) | KCNH2MAPTMAOASLC6A2SLC6A4 | |
| Theracys SCHEMBL18648964 | 0.82 | KCNH2 (0.80) | KCNH2MAPTMAOASLC6A2SLC6A4 | |
| Theracys SCHEMBL16922152 | 0.82 | KCNH2 (0.80) | KCNH2MAPTMAOASLC6A2SLC6A4 | |
| Theracys SCHEMBL328884 | 0.82 | KCNH2 (0.80) | KCNH2MAPTMAOASLC6A2SLC6A4 | |
| SCHEMBL9256363 | 0.82 | CHRM2 (0.66) | CHRM2CHRM4CHRM1CHRM3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100209449-A1 | HAPTEN-CARRIER CONJUGATES FOR USE IN DRUG-ABUSE THERAPY AND METHODS FOR PREPARATION OF SAME | SWAIN PHILIP A | 2010-08-19 | — | — | US | disclosed |
| US-20100105672-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | SWAIN PHILIP A | 2010-04-29 | — | — | US | disclosed |
| US-20100068222-A1 | Hapten-carrier conjugates for use in drug abuse therapy and methods for preparation of same | SWAIN PHILIP A | 2010-03-18 | — | — | US | disclosed |
| US-20060286097-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | XENOVA RESEARCH LTD. | 2006-12-21 | — | — | US | disclosed |
| US-20060286096-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | XENOVA RESEARCH LTD. | 2006-12-21 | — | — | US | disclosed |
| US-20060286094-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | XENOVA RESEARCH LTD. | 2006-12-21 | — | — | US | disclosed |
| US-20060286095-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | XENOVA RESEARCH LTD. | 2006-12-21 | — | — | US | disclosed |
| US-20060286099-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | XENOVA RESEARCH LTD. | 2006-12-21 | — | — | US | disclosed |
| US-20060286098-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | XENOVA RESEARCH LTD. | 2006-12-21 | — | — | US | disclosed |
| US-20060280736-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | XENOVA RESEARCH LTD. | 2006-12-14 | — | — | US | disclosed |
| EP-1466913-A1 | Benzoylecgonine, ecgonine and ecgonidine derivatives | ENTROPIN, INC. (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-0765326-B1 | BENZOYLECGONINE, ECGONINE AND ECGONIDINE DERIVATIVES | ENTROPIN INC (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030069400-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | XENOVA RESEARCH LIMITED | 2003-04-10 | — | — | US | disclosed |
| US-20020177714-A1 | Benzoylecgonine, ecgonine and ecgonidine derivatives | ENTROPIN, INC. | 2002-11-28 | — | — | US | disclosed |
| US-20020032316-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | CANTAB PHARMACEUTICALS RESEARCH LIMITED | 2002-03-14 | — | — | US | disclosed |
| US-6077848-A | 8-METHYL-8-AZABICYCLO(3.2.1)OCTANE ESTERS ARE USEFUL FOR TREATING THE SYMPTOMS OF IMMUNOREGULATORY DISORDERS, NEUROMUSCULAR DISORDERS, JOINT DISORDERS, CONNECTIVE TISSUE DISORDERS, CIRCULATORY SYSTEM DISORDERS OR PAIN | ENTROPIN, INC. (US) | 2000-06-20 | — | — | US | disclosed |
| US-6054127-A | A THERAPEUTIC TREATMENT FOR COCAINE ADDICTION; THE CONJUGATE CAPABLE OF STIMULATING THE PRODUCTION OF ANTI-HAPTEN ANTIBODIES; A THERAPEUTIC IMMUNIZATION REGIMEN ELICITS ANTI-DRUG ANTIBODIES | IMMULOGIC PHARMACEUTICAL CORPORATION (US) | 2000-04-25 | — | — | US | disclosed |
| EP-0765326-A1 | BENZOYLECGONINE, ECGONINE AND ECGONIDINE DERIVATIVES | ENTROPIN, INC. (US) | 1997-04-02 | — | — | EP | disclosed |
| US-5525613-A | Covalently coupled benzoylecgonine ecgonine and ecgonidine | ENTROPIN, INC. (US) | 1996-06-11 | — | — | US | disclosed |
| WO-1995034561-A1 | BENZOYLECGONINE, ECGONINE AND ECGONIDINE DERIVATIVES | ENTROPIN, INC. (US) | 1995-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100209449-A1 | HAPTEN-CARRIER CONJUGATES FOR USE IN DRUG-ABUSE THERAPY AND METHODS FOR PREPARATION OF SAME | CES2, CD44, CD47 | CHRM2 274/4885CHRM4 142/4885CHRM1 188/4885 |
| US-20100105672-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | CES2, CD44, CD47 | CHRM2 274/4885CHRM4 142/4885CHRM1 188/4885 |
| US-20060280736-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | CES2, CD44, CD47 | CHRM2 274/4885CHRM4 142/4885CHRM1 188/4885 |
| US-20020177714-A1 | Benzoylecgonine, ecgonine and ecgonidine derivatives | TNNT2, TNNC1, TNNI3 | CHRM2 501/4885CHRM4 1175/4885CHRM1 808/4885 |
| US-20100068222-A1 | Hapten-carrier conjugates for use in drug abuse therapy and methods for preparation of same | CES2, CD47, CD44 | CHRM2 276/4885CHRM4 150/4885CHRM1 200/4885 |
| US-20060286095-A1 | Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same | CES2, CD44, CD47 | CHRM2 274/4885CHRM4 142/4885CHRM1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.